In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

U.S. division has sued CMS over the Medicare drug pricing negotiations policy included in the Inflation Reduction Act. In its ...

As 2024 has come and passed, we saw another year of significant developments in litigation involving biologics and biosimilars. The ...

Samsung Bioepis and Teva have entered into a license, development and commercialization agreement for Epysqli ...

New partnerships aim to expand Teva’s biosimilar portfolio and enhance access to high-cost biologics across key markets.

Teva Pharmaceutical (NYSE:TEVA) has entered into a strategic collaboration with Klinge Biopharma and Formycon AG, for the ...

EPYSQLI is a complement inhibitor indicated for the treatment of rare disease patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to ...

South Korean biosimilars developer Samsung Bioepis and Israel’s Teva Pharmaceutical Industries have entered into a license, development and commercialization agreement for Epysqli (eculizumab-aagh), ...

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...